SQZ Biotech Competitors and Similar CompaniesClear all
SQZ Biotech's competitors and similar companies include Ultivue, Onconova Therapeutics, Statera Biopharma and CytomX Therapeutics.
 SQZ Biotech SQZ Biotechnologies is a company that develops cell therapies for patients with cancer and infectious diseases. |  Onconova Therapeutics Onconova Therapeutics is a biopharmaceutical company developing small molecule drug candidates for the treatment of cancer. |  Statera Biopharma Statera Biopharma (formerly known as Cytocom) is a pre-clinical and clinical biopharmaceutical company that develops product candidates for treating diseases involving immune system dysfunction. |  CytomX Therapeutics CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform. | ||
Founding Date | Founding Date 2013 | Founding Date 2015 | Founding Date 1998 | Founding Date 2003 | Founding Date 2008 |
Type | Type Public | Type Private | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Watertown, US HQ | Locations Cambridge, US HQ Segrate, IT | Locations Newtown, US HQ Boston, US Newtown, US Pennington, US | Locations Fort Collins, US HQ Fort Collins, US | Locations South San Francisco, US HQ |
Employees | Employees 5353% decrease | Employees 512% decrease | Employees 1732% decrease | Employees 16 | Employees 15815% increase |
Valuation ($) | Valuation ($) 12.8 m | Valuation ($) N/A | Valuation ($) 20.9 m | Valuation ($) 21.4 k | Valuation ($) 78 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $21.5m (FY, 2022) | Revenue (est.) N/A | Revenue (est.) $226k (FY, 2023) | Revenue (est.) $1.5m (FY, 2021) | Revenue (est.) $101.2m (FY, 2023) |
Net income | Net income ($79.5m) (FY, 2022) | Net income N/A | Net income ($18.9m) (FY, 2023) | Net income ($101.9m) (FY, 2021) | Net income ($569k) (FY, 2023) |
Operating ⚠ | |||||
Phase I Trials Products | Phase I Trials Products 1 (Q2, 2020) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 1 (FY, 2016) |
Pre-Clinical Phase Products | Pre-Clinical Phase Products 10 (Q2, 2020) | Pre-Clinical Phase Products N/A | Pre-Clinical Phase Products N/A | Pre-Clinical Phase Products N/A | Pre-Clinical Phase Products 4 (FY, 2016) |
Funding | |||||
Total funding raised | Total funding raised $ 233.4m | Total funding raised $ 57.3m | Total funding raised $ 88m | Total funding raised $ 12.2m | Total funding raised $ 132.4m |
For sources of this data, please see the company profile
View Company Profiles
Ultivue
HQ
Cambridge, US
Employees
51↓ 2% decrease
Ultivue operates in the biotechnology industry.
View companyOnconova Therapeutics
HQ
Newtown, US
Employees
17↓ 32% decrease
Onconova Therapeutics is a biopharmaceutical company developing small molecule drug candidates for the treatment of cancer.
View companyStatera Biopharma
HQ
Fort Collins, US
Employees
16
Statera Biopharma (formerly known as Cytocom) is a pre-clinical and clinical biopharmaceutical company that develops product candidates for treating diseases involving immune system dysfunction.
View companyCytomX Therapeutics
HQ
South San Francisco, US
Employees
158↑ 15% increase
CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform.
View company